Allworth Financial’s Monopar Therapeutics MNPR Stock Holding History
Bought
Maintained
Sold
Other funds holding MNPR
SVCM
SL
Allworth Financial's MNPR Position: Q3 2026 in Review
Allworth Financial increased its Monopar Therapeutics (MNPR) stake by 5.4% in Q3 2026, buying an estimated $643 and bringing the position to 117 shares worth $9.32K. The position accounts for ﹤0.01% of the portfolio, ranked #4103.
Allworth Financial first reported a position in MNPR in Q1 2025 and has held it in 7 quarters since. The position peaked at $10.3K in Q2 2026. 106 funds tracked by Wall St. Rank hold MNPR as of Q3 2026.
- Allworth Financial held 117 shares of Monopar Therapeutics worth $9.32K as of Q3 2026.
- Allworth Financial bought 6 Monopar Therapeutics shares in Q3 2026, an estimated $643.
- Monopar Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q3 2026, its #4103 holding.
- Allworth Financial first reported a position in Monopar Therapeutics in Q1 2025 and has held it in 7 quarters since.
- Allworth Financial's Monopar Therapeutics position peaked at $10.3K in Q2 2026.
- 106 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q3 2026.
Based on Allworth Financial's 13F filing for Q3 2026, filed 6 Nov 2026.